Revenue and EBITDA guidance raised

In the second quarter of the financial year 2021/22, ChemoMetec continued its positive development. Sales and order intake in especially the North American market developed significantly better than expected. Furthermore, the USD has strengthened in the first five months of the financial year. The global supply situation of raw materials has not yet impacted ChemoMetec's ability to supply finished products, and we have been able to maintain production, quality control and logistics functions at a satisfactory level thus far.

However, there is increasing uncertainty regarding a number of factors in the coming period. There is increasing uncertainty about the future supply situation should the global component shortage continue into 2022, and moreover, there is upward pressure on purchasing prices in general. In addition, the challenges regarding Covid-19 are increasing again. ChemoMetec follows the developments in the individual areas closely and seeks to adapt its activities to the current conditions in the best possible way.

Based on the above, ChemoMetec now expects revenue in the financial year 2021/22 in the DKK 370-380 million range, up from DKK 335-345 million, and EBITDA is expected to be in DKK 175-180 million range, up from DKK 160-165 million.

For further information

Steen Søndergaard, CEO, ChemoMetec A/S

Phone: (+45) 4813 1020

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec's instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec's customers include some of the world's leading pharmaceutical companies such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For more information, go to www.chemometec.com.